Press release BoxID: 792460 (Lonza Group Ltd.)
  • Lonza Group Ltd.
  • Münchensteinerstraße 38
  • 4002 Basel
  • Contact person
  • Dirk Oehlers
  • +41 (61) 316-8540

Lonza Announces Results of the 2016 Annual General Meeting - Annual General Meeting Accepts All Motions Proposed by Board of Directors

(PresseBox) (Basel, ) .

Shareholders re-elected all existing members of the Board of Directors and approved the new election of Christoph Mäder
Rolf Soiron was re-elected as Board Chairperson for another year
202 shareholders attended, representing 59.81% of the share capital
A dividend of CHF 2.50 per share will be paid out as of 28 April 2016
More than 90% of shareholders supported each of the proposed motions

Today’s Annual General Meeting of Lonza Group Ltd, led by the Chairperson of the Board of Directors, Rolf Soiron, was attended by 202 shareholders. They represented 59.81% of the share capital.

The Board members standing for re-election (Rolf Soiron, Patrick Aebischer, Werner Bauer, Thomas Ebeling, Jean-Daniel Gerber, Barbara Richmond, Margot Scheltema, Juergen Steinemann and Antonio Trius) were all elected for a further term in office of one year. The shareholders elected Christoph Mäder as a new member of the Board. The Annual General Meeting also re-elected Rolf Soiron as Chairperson of the Board of Directors for a further term in office of one year, as well as the three acting members of the Nomination and Compensation Committee.

The shareholders strongly supported all other motions proposed by the Board of Directors, including among others the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.

A dividend of CHF 2.50 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out from 28 April 2016.

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.

For further information, please see the short form minutes of the Lonza Annual General Meeting under the following link (select “Annual General Meeting 2016”).


Lonza Group Ltd.

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at